{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:14:24Z","timestamp":1791648864044,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006190","name":"VA Office of Research & Development","doi-asserted-by":"publisher","award":["5I01CX001513"],"award-info":[{"award-number":["5I01CX001513"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clinthera.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T12:14:56Z","timestamp":1681128896000},"page":"468-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pilot Study of Low-dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial"],"prefix":"10.1016","volume":"45","author":[{"given":"Britte","family":"Beaudette-Zlatanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Otis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Bacorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Eyvazzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio A.","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Libbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Monach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.03.013_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis and rheumatism"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0002","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/BOR.0000000000000479","article-title":"Epidemiology of osteoarthritis: literature update","volume":"30","author":"Vina","year":"2018","journal-title":"Current opinion in rheumatology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0003","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.30498","article-title":"Incidence of physician-diagnosed osteoarthritis among active duty United States military service members","volume":"63","author":"Cameron","year":"2011","journal-title":"Arthritis and rheumatism"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2018.0899","article-title":"Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial","volume":"319","author":"Krebs","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7326\/M14-1231","article-title":"Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis","volume":"162","author":"Bannuru","year":"2015","journal-title":"Annals of internal medicine"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0039-1679919","article-title":"Acetaminophen Hepatotoxicity","volume":"39","author":"Ramachandran","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0007","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X","article-title":"A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee","volume":"44","author":"Pincus","year":"2001","journal-title":"Arthritis and rheumatism"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0008","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis care & research"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0009","article-title":"Acetaminophen for osteoarthritis","volume":"1","author":"Towheed","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semarthrit.2019.07.012","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication","volume":"50","author":"Braun","year":"2019","journal-title":"Seminars in arthritis and rheumatism"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.03.013_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40266-019-00660-1","article-title":"Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?","volume":"36","author":"Cooper","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0012","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/art.41142","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee","volume":"72","author":"Kolasinski","year":"2020","journal-title":"Arthritis & rheumatology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-017-1292-2","article-title":"Structural predictors of response to intra-articular steroid injection in symptomatic knee osteoarthritis","volume":"19","author":"Maricar","year":"2017","journal-title":"Arthritis research & therapy"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0014","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1007\/s10067-019-04656-5","article-title":"Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing","volume":"38","author":"Ramjeeawon","year":"2019","journal-title":"Clinical rheumatology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11914-018-0477-1","article-title":"Mechanisms of Osteoarthritis (OA) Pain","volume":"16","author":"O'Neill","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0016","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.37920","article-title":"Neuropathic pain in ankylosing spondylitis: a psychophysics and brain imaging study","volume":"65","author":"Wu","year":"2013","journal-title":"Arthritis and rheumatism"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrrheum.2014.47","article-title":"Osteoarthritis pain: nociceptive or neuropathic?","volume":"10","author":"Thakur","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0018","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3899\/jrheum.140382","article-title":"The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive","volume":"42","author":"Orlowsky","year":"2015","journal-title":"Journal of rheumatology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fnmol.2017.00349","article-title":"Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models","volume":"10","author":"Eitner","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Annals of neurology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease","volume":"102","author":"Smith","year":"2007","journal-title":"The American journal of gastroenterology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study","volume":"47","author":"Smith","year":"2013","journal-title":"Journal of clinical gastroenterology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0023","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis and rheumatism"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0024","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1007\/s10620-006-9289-8","article-title":"Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study","volume":"51","author":"Kariv","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/pme.12345","article-title":"Off-label, low-dose naltrexone for refractory chronic low back pain","volume":"15","author":"Ghai","year":"2014","journal-title":"Pain medicine"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0026","first-page":"790","article-title":"Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy","volume":"17","author":"Hota","year":"2016","journal-title":"Pain medicine"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0027","first-page":"e4225","article-title":"Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy","volume":"11","author":"Zashin","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbr.2018.11.039","article-title":"Antagonism of mu-opioid receptors reduces sensation seeking-like behavior in mice","volume":"359","author":"Sikora","year":"2019","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0029","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clinical rheumatology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.npep.2016.06.003","article-title":"Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats","volume":"59","author":"Tawfik","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0032","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders","volume":"38","author":"Patten","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0033","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpain.2005.06.002","article-title":"Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis","volume":"10","author":"Mendoza","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0034","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain medicine"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0035","first-page":"E393","article-title":"Low-dose naltrexone use for patients with chronic regional pain syndrome: a systematic literature review","volume":"24","author":"Soin","year":"2021","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0036","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.adaj.2020.08.019","article-title":"Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review","volume":"151","author":"Hatfield","year":"2020","journal-title":"Journal of the American Dental Association"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0037","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1049909119838974","article-title":"Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes","volume":"36","author":"Trofimovitch","year":"2019","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0038","doi-asserted-by":"crossref","first-page":"8429","DOI":"10.3390\/ijms22168429","article-title":"Immunometabolic modulatory role of naltrexone in BV-2 microglia cells","volume":"22","author":"Kucic","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0039","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bph.12790","article-title":"Effect of naltrexone on neuropathic pain in mice locally transfected with the mutant mu-opioid receptor gene in spinal cord","volume":"172","author":"Kao","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107144","article-title":"Long-acting opioids and cardiovascular diseases: help or hindrance!","volume":"149","author":"Mehta","year":"2023","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0041","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/ijms24032812","article-title":"Evidence for endogenous opioid dependence related to latent sensitization in a rat model of chronic inflammatory pain","volume":"24","author":"Morales-Medina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0042","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109328","article-title":"Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates","volume":"223","author":"Ding","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0044","first-page":"e10436","article-title":"Cannabinoid receptors and their relationship with chronic pain: a narrative review","volume":"12","author":"Anthony","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","article-title":"Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis","volume":"17","author":"Bolton","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0046","series-title":"Vivitrol\u00ae [package insert]","year":"1984"},{"key":"10.1016\/j.clinthera.2023.03.013_bib0047","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmj.332.7534.132","article-title":"Naltrexone and problems in pain management","volume":"332","author":"Vickers","year":"2006","journal-title":"BMJ"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T19:05:28Z","timestamp":1719342328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0149291823001133"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Study of Low-dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}